Agilent to Acquire Resolution Bioscience, Strengthening Leadership Position in Cancer Diagnostics
- Resolution Bioscience is a fast-growing, innovative leader in next-generation sequencing (NGS)-based oncology solutions.
- Combination brings together Resolution Bioscience?s noninvasive liquid biopsy platform that improves cancer diagnostics with Agilent?s leadership in tissue-based companion diagnostics and global commercial and regulatory scale.
- Furthers Agilent?s participation in fast-growing NGS technologies for precision oncology, expanding Agilent?s addressable market by $3 billion in 2025 with that figure estimated to double by 2030.